Zenas BioPharma Receives 'Moderate Buy' Consensus Rating from Analysts

The biotech firm's stock has a 1-year average price target of $43.14 per share.

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

Zenas BioPharma, Inc. (NASDAQ:ZBIO) has received a 'Moderate Buy' consensus rating from the eight research firms covering the company, according to Marketbeat.com. One analyst has a 'sell' recommendation, one has a 'hold' rating, and six have assigned 'buy' ratings to the stock.

Why it matters

Zenas BioPharma is a clinical-stage biotech company focused on developing novel therapies in oncology and infectious diseases. The 'Moderate Buy' consensus from analysts suggests they see potential in the company's pipeline and business model, despite some mixed ratings.

The details

The average 1-year price target for Zenas BioPharma's stock is $43.14 per share. Analysts have cited the company's proprietary platform that integrates structure-guided design, computational modeling, and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options.

  • Zenas BioPharma was founded in 2021 and is headquartered in Cambridge, Massachusetts.
  • The company's stock opened at $25.28 per share on Friday.

The players

Zenas BioPharma, Inc.

A clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases.

Marketbeat.com

A financial media company that provides stock market news, data, and analysis.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

Zenas BioPharma's 'Moderate Buy' consensus rating from analysts suggests the company's innovative drug discovery platform and pipeline have potential, though there are still some mixed views on the stock's outlook.